Form 4: Progyny Director Debra Morris Receives Stock Options Valued at $40,000 as Board Compensation

Progyny, Inc. Director Debra L. Morris acquired 3,591 stock options with an exercise price of $20.89, granted on May 22, 2025, in lieu of a $40,000 annual cash retainer for board service, with vesting scheduled for May 22, 2026.

Summary

• Debra L. Morris, a Director of Progyny, Inc. (PGNY), acquired 3,591 stock options on May 22, 2025.
• These options were issued as compensation, replacing an annual cash retainer of $40,000 for her board service.
• The stock options have an exercise price of $20.89 per share.
• The underlying shares will vest on May 22, 2026, contingent upon Ms. Morris's continued service on the board.
• The options are set to expire on May 21, 2035.
• Following this transaction, Ms. Morris directly beneficially owns 3,591 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a routine compensation event for a director, aligning their interests with shareholders through equity. It's a neutral to slightly positive event as it conserves cash and aligns incentives, but doesn't reflect operational performance or significant new strategic developments.

Positives

• The issuance of stock options aligns the director's financial interests with those of the company's shareholders, promoting long-term value creation.
• By granting options in lieu of a cash retainer, Progyny potentially conserves cash resources.

Risks

• The vesting of the stock options is conditional on Debra L. Morris's continued service as a director until May 22, 2026.
• The ultimate value realized from these options is dependent on Progyny's stock price exceeding the exercise price of $20.89 per share at the time of exercise.

Future Outlook

The future financial benefit from these options for the director is contingent on Progyny's stock performance, specifically if its share price exceeds the $20.89 exercise price by the vesting date of May 22, 2026, and prior to the options' expiration on May 21, 2035.

Management Comments

• "The option was issued to the Reporting Person in lieu of an annual cash retainer of $40,000 for board service. The shares subject to the option will vest on May 22, 2026, subject to the Reporting Person's continued service on such date."

Industry Context

This transaction reflects a common practice in corporate governance across various industries, where public companies utilize equity-based compensation, such as stock options, to incentivize and align the interests of their non-executive directors with those of shareholders. This method is widely adopted to foster long-term commitment and performance.

Comparison to Industry Standards

• The practice of compensating directors with equity, specifically stock options, is a widely accepted and standard practice among U.S. public companies, including those in the healthcare technology sector where Progyny operates.
• This compensation structure is often favored as it directly links director incentives to the company's stock performance and shareholder value creation, which is a key benchmark for effective corporate governance and aligns with best practices observed in comparable companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's long-term interests with shareholder value creation.
• Company: The company benefits from potential cash conservation by issuing options instead of a cash retainer.

Next Steps

• Debra L. Morris is expected to continue her board service until at least May 22, 2026, for the granted options to vest.
• Progyny, Inc.'s ongoing operational and financial performance will influence the ultimate value of these stock options.

Key Dates

Keywords

Progyny, PGNY, Form 4, SEC filing, stock options, insider transaction, director compensation, equity compensation, beneficial ownership